Oral Session 1-12D CLL

[OS1-12D-2] Phase 1 study of ibrutinib in Japanese patients with treatment-naive CLL/SLL

Takanori Teshima¹, Hirohiko Shibayama², Ilseung Choi³, Kiyohiko Hatake⁴, Naohiro Sekiguchi⁵, Nozomi Yoshinari⁶ (1.Faculty of Medicine, Hokkaido Univ., Sapporo, Japan, 2.Osaka Univ. Grad. Schl. Med., Osaka, Japan, 3.NHO Kyusyu Cancer Ctr., Fukuoka, Japan, 4.The Cancer Institute Hosp. JFCR, Tokyo, Japan, 5.NHO Disaster Med. Ctr., Tachikawa, Japan, 6.Janssen Pharmaceutical K.K, Tokyo, Japan)